Jiachao Liang
Ohio State University
10 Papers
76 Citations
Jiachao Liang is an academic researcher from Ohio State University. The author has contributed to research in topics: Magnetic resonance imaging & Medicine. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos,Matthew D. Ringel,Michael V. Knopp,Nathan Hall,Mark A. King,Robert Stevens,Jiachao Liang,Paul E. Wakely,Vasyl Vasko,Motoyasu Saji,Jennifer Rittenberry,Lai Wei,Daria Arbogast,Minden Collamore,John J. Wright,Michael R. Grever,Manisha H. Shah +16 more
TL;DR: Sorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC and four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylated, ERK phosphorylation, and in VEGF expression during sorafenIB therapy.
Improving the pharmacokinetic parameter measurement in dynamic contrast‐enhanced MRI by use of the arterial input function: Theory and clinical application
Xiangyu Yang,Jiachao Liang,Johannes T. Heverhagen,Guang Jia,Petra Schmalbrock,Steffen Sammet,R. M. Koch,Michael V. Knopp +7 more
TL;DR: Tissue‐type classifier constructed with the arterial input function–decomposed kep‐kpe pair from the model was demonstrated to have superior performance than any other classifier based on DCE‐MRI pharmacokinetic parameters or empirical AUC, and has a near‐zero false‐negative rate.
32
Colorectal liver metastases: contrast agent diffusion coefficient for quantification of contrast enhancement heterogeneity at MR imaging.
Guang Jia,Craig O'Dell,Johannes T. Heverhagen,Xiangyu Yang,Jiachao Liang,Richard Jacko,Steffen Sammet,Theodore Pellas,Patricia E. Cole,Michael V. Knopp +9 more
TL;DR: The CDC enables a quantitative description of contrast enhancement heterogeneity in lesions and appears promising for further qualification as an imaging biomarker of change measurement in response assessment.
21
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
Wen Li,Nu N. Le,Natsuko Onishi,David C. Newitt,Lisa J. Wilmes,Jessica Gibbs,Julia C. Carmona-Bozo,Jiachao Liang,Savannah C. Partridge,Elissa R. Price,Bonnie N. Joe,John Kornak,Mark Jesus M. Magbanua,Rita Nanda,B. Lestage,Laura J. Esserman,I-Spy Imaging Working Group,I-Spy Investigator Network,Laura J. van't Veer,Nola M. Hylton +19 more
TL;DR: It is found diffusion-weighted MRI is superior to dynamic contrast-enhanced MRI, where the latter is a standard and most-commonly used MRI modality, in assessing immunotherapy, while no significant difference was observed in the control cohort where only standard chemotherapy was provided.
15
Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
TL;DR: Gd chelate containing MR contrast agents can be used at 7T for DCEMRI, and Gd-BOPTA demonstrates stronger signal enhancement than standard Gd chelates, in concordance with the results of studies at lower fields.
15